Key facts
- This page summarizes UNITED BIOMEDICAL INC's Form 4 filing for Vaxxinity, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jun 2022, 16:52.
UNITED BIOMEDICAL INC - 16 Jun 2022 Form 4 Insider Report for Vaxxinity, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 16 Jun 2022
- Net transaction value
- +$199,290
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2022, 16:52:22 UTC
- Prior SEC filing
- 10 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mei Mei Hu, As Director and Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
UNITED BIOMEDICAL INC filed Form 4 for Vaxxinity, Inc. on 21 Jun 2022.
Change
- Previous filing in this sequence was filed on 10 Jun 2022.
- Current net transaction value: +$199,290.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VAXX
transaction
Class A common stock
Purchase
- Transaction value
- $199,290
- Shares
- +100,000
- Change %
- +0.19%
- Price
- $1.99
- Shares after
- 51,737,344
- Date
- 16 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
VAXX
holding
Class A common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,212,495
- Date
- 16 Jun 2022
- Ownership
- Held by United Biomedical Inc., Asia
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported is a weighted average price.
Footnote F2
Held by United Biomedical, Asia Inc. ("UBIA"). The Reporting Person, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBIA in which the Reporting Person has no pecuniary interest.